713 related articles for article (PubMed ID: 25476752)
21. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
[No Abstract] [Full Text] [Related]
22. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
[TBL] [Abstract][Full Text] [Related]
23. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
Zhao C; Yang ZY; Zhang J; Li O; Liu SL; Cai C; Shu YJ; Pan LJ; Gong W; Dong P
J Transl Med; 2022 Sep; 20(1):434. PubMed ID: 36180918
[TBL] [Abstract][Full Text] [Related]
26. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.
Perwitasari O; Johnson S; Yan X; Howerth E; Shacham S; Landesman Y; Baloglu E; McCauley D; Tamir S; Tompkins SM; Tripp RA
J Virol; 2014 Sep; 88(17):10228-43. PubMed ID: 24965445
[TBL] [Abstract][Full Text] [Related]
27. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
[TBL] [Abstract][Full Text] [Related]
28. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
29. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
Etchin J; Sun Q; Kentsis A; Farmer A; Zhang ZC; Sanda T; Mansour MR; Barcelo C; McCauley D; Kauffman M; Shacham S; Christie AL; Kung AL; Rodig SJ; Chook YM; Look AT
Leukemia; 2013 Jan; 27(1):66-74. PubMed ID: 22847027
[TBL] [Abstract][Full Text] [Related]
30. XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor.
Pan L; Cheng C; Duan P; Chen K; Wu Y; Wu Z
J Exp Clin Cancer Res; 2021 Aug; 40(1):255. PubMed ID: 34384466
[TBL] [Abstract][Full Text] [Related]
31. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
32. XPO1-dependent nuclear export as a target for cancer therapy.
Azizian NG; Li Y
J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
[TBL] [Abstract][Full Text] [Related]
33. Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
[TBL] [Abstract][Full Text] [Related]
34. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Walker CJ; Oaks JJ; Santhanam R; Neviani P; Harb JG; Ferenchak G; Ellis JJ; Landesman Y; Eisfeld AK; Gabrail NY; Smith CL; Caligiuri MA; Hokland P; Roy DC; Reid A; Milojkovic D; Goldman JM; Apperley J; Garzon R; Marcucci G; Shacham S; Kauffman MG; Perrotti D
Blood; 2013 Oct; 122(17):3034-44. PubMed ID: 23970380
[TBL] [Abstract][Full Text] [Related]
35. CRM1-mediated nuclear export of proteins and drug resistance in cancer.
Turner JG; Sullivan DM
Curr Med Chem; 2008; 15(26):2648-55. PubMed ID: 18991627
[TBL] [Abstract][Full Text] [Related]
36. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
Lapalombella R; Sun Q; Williams K; Tangeman L; Jha S; Zhong Y; Goettl V; Mahoney E; Berglund C; Gupta S; Farmer A; Mani R; Johnson AJ; Lucas D; Mo X; Daelemans D; Sandanayaka V; Shechter S; McCauley D; Shacham S; Kauffman M; Chook YM; Byrd JC
Blood; 2012 Nov; 120(23):4621-34. PubMed ID: 23034282
[TBL] [Abstract][Full Text] [Related]
38. Clinical translation of nuclear export inhibitors in cancer.
Senapedis WT; Baloglu E; Landesman Y
Semin Cancer Biol; 2014 Aug; 27():74-86. PubMed ID: 24755012
[TBL] [Abstract][Full Text] [Related]
39. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
